InsiderTrades.com logo

Michael Austwick Biography and Net Worth

Director of Verona Pharma PLC American Depositary Share
  • Phone
  • Email
  • Website


Mr Austwick was appointed to the board as a Non-Executive Director in February 2024.

Mr Austwick has a wealth of strategic and operational experience in the biopharmaceutical industry including more than 15 years of respiratory expertise in leadership roles across the US, China, Europe and Japan. He is Executive Vice President Global Commercial at New Amsterdam Pharma, a public company developing treatments for cardiovascular disease and other lipid-related conditions. From June 2022 to November 2023, he served as CEO at Vectura, and previously as Nordic General Manager and Head of the Global Respiratory Franchise at Novartis and as Head of US Respiratory and Vice President Global Inhaled Respiratory at AstraZeneca. Mr Austwick has led the development and commercialization of more than 10 brands, covering inhaled and biologic assets at a country and global level. He has an MSc in Information Management from the University of Hull and a BSc in Management and Systems from City University, London.

What is Michael Austwick's net worth?

The estimated net worth of Michael Austwick is at least $1.36 million as of August 1st, 2025. Mr. Austwick owns 12,712 shares of Verona Pharma PLC American Depositary Share stock worth more than $1,359,040 as of December 4th. This net worth estimate does not reflect any other investments that Mr. Austwick may own. Learn More about Michael Austwick's net worth.

How do I contact Michael Austwick?

The corporate mailing address for Mr. Austwick and other Verona Pharma PLC American Depositary Share executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma PLC American Depositary Share can also be reached via phone at 011-44-0-2032834200 and via email at [email protected]. Learn More on Michael Austwick's contact information.

Has Michael Austwick been buying or selling shares of Verona Pharma PLC American Depositary Share?

Michael Austwick has not been actively trading shares of Verona Pharma PLC American Depositary Share during the last quarter. Most recently, Michael Austwick sold 11,288 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $13.14, for a transaction totalling $148,324.32. Following the completion of the sale, the director now directly owns 12,712 shares of the company's stock, valued at $167,035.68. Learn More on Michael Austwick's trading history.

Who are Verona Pharma PLC American Depositary Share's active insiders?

Verona Pharma PLC American Depositary Share's insider roster includes Christina Ackermann (Director), Michael Austwick (Director), James Brady (Director), Kenneth Cunningham (Director), Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Andrew Fisher (General Counsel), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Mahendra Shah (Director), Vikas Sinha (Director), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma PLC American Depositary Share's active insiders.

Are insiders buying or selling shares of Verona Pharma PLC American Depositary Share?

In the last year, insiders at the sold shares 32 times. They sold a total of 3,057,968 shares worth more than $30,187,074.16. The most recent insider tranaction occured on August, 1st when Director Kenneth Cunningham sold 10,808 shares worth more than $142,017.12. Insiders at Verona Pharma PLC American Depositary Share own 4.8% of the company. Learn More about insider trades at Verona Pharma PLC American Depositary Share.

Information on this page was last updated on 8/1/2025.

Michael Austwick Insider Trading History at Verona Pharma PLC American Depositary Share

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/1/2025Sell11,288$13.14$148,324.3212,712View SEC Filing Icon  
See Full Table

Michael Austwick Buying and Selling Activity at Verona Pharma PLC American Depositary Share

This chart shows Michael Austwick's buying and selling at Verona Pharma PLC American Depositary Share by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Verona Pharma PLC American Depositary Share Company Overview

Verona Pharma PLC American Depositary Share logo
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $106.91
Low: $106.91
High: $106.91

50 Day Range

MA: $106.65
Low: $105.91
High: $106.95

2 Week Range

Now: $106.91
Low: $31.09
High: $106.93

Volume

N/A

Average Volume

1,457,608 shs

Market Capitalization

$9.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05